today announced that mature outcomes from a Phase 1/2 research evaluating CDX-011 in advanced stage breast cancers patients were shown at the 46th Annual Interacting with of the American Culture of Clinical Oncology . CDX-011 can be an experimental antibody-drug conjugate directed against glycoprotein NMB and associated with a potent tumor cell-killing drug, monomethyl-auristatin E . ‘The results in triple unfavorable disease are especially encouraging,’ stated Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. ‘A subset analysis using a recently optimized diagnostic assay for GPNMB demonstrated that patients with strong stromal or tumor cell expression of GPNMB may be most likely to react to CDX-011.’ Related StoriesViralytics enters into clinical trial collaboration contract with MSDMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patientsNew findings reveal association between colorectal cancer tumor and melanoma medications’A reliable and marketable assay to detect a target antigen is critical in the development of any targeted therapy,’ said Tom Davis, M.D., Chief Medical Officer of Celldex Therapeutics.Recently there has been some debate about the function celiac disease may play in fertility problems. Celiac diseaseCeliac disease is definitely a condition where the lining of the small intestine becomes damaged because of wheat sensitivity. The fine lining or villi in the tiny intestine is in charge of absorbing vital nutrients from the meals you eat, and when they become broken it can cause a wide variety of medical complications including rashes, IBS, malnutrition plus much more. It might be hard to imagine that celiac disease could possess any relation to infertility, however, many extensive research is starting to point in that direction.